Literature DB >> 27974563

Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Michael A Angelo1, Alba Grifoni1, Patrick H O'Rourke1, John Sidney1, Sinu Paul1, Bjoern Peters1, Aruna D de Silva1,2, Elizabeth Phillips3, Simon Mallal3, Sean A Diehl4, Beth D Kirkpatrick4, Stephen S Whitehead5, Anna P Durbin6, Alessandro Sette1, Daniela Weiskopf7.   

Abstract

Dengue virus (DENV) is responsible for growing numbers of infections worldwide and has proven to be a significant challenge for vaccine development. We previously demonstrated that CD8+ T cell responses elicited by a dengue live attenuated virus (DLAV) vaccine resemble those observed after natural infection. In this study, we screened peripheral blood mononuclear cells (PBMCs) from donors vaccinated with a tetravalent DLAV vaccine (TV005) with pools of dengue virus-derived predicted major histocompatibility complex (MHC) class II binding peptides. The definition of CD4+ T cell responses after live vaccination is important because CD4+ T cells are known contributors to host immunity, including cytokine production, help for CD8+ T and B cells, and direct cytotoxicity against infected cells. While responses to all antigens were observed, DENV-specific CD4+ T cells were focused predominantly on the capsid and nonstructural NS3 and NS5 antigens. Importantly, CD4+ T cell responses in vaccinees were similar in magnitude and breadth to those after natural infection, recognized the same antigen hierarchy, and had similar profiles of HLA restriction. We conclude that TV005 vaccination has the capacity to elicit CD4+ cell responses closely mirroring those observed in a population associated with natural immunity.IMPORTANCE The development of effective vaccination strategies against dengue virus infection is of high global public health interest. Here we study the CD4 T cell responses elicited by a tetravalent live attenuated dengue vaccine and show that they resemble responses seen in humans naturally exposed to dengue virus. This is an important issue, since it is likely that optimal immunity induced by a vaccine requires induction of CD4+ responses against the same antigens as those recognized as dominant in natural infection. Detailed knowledge of the T cell response may further contribute to the identification of robust correlates of protection against dengue virus.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD4; CD4+ T cell; HLA; MHC; T cells; TV005; dengue virus; live attenuated; live attenuated vaccine; tetravalent; vaccines

Mesh:

Substances:

Year:  2017        PMID: 27974563      PMCID: PMC5309943          DOI: 10.1128/JVI.02147-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Heterogeneity of Human CD4(+) T Cells Against Microbes.

Authors:  Federica Sallusto
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

2.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.

Authors:  Daniela Weiskopf; Michael A Angelo; Elzinandes L de Azeredo; John Sidney; Jason A Greenbaum; Anira N Fernando; Anne Broadwater; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Kimberly A Mattia; Benjamin J Doranz; Howard M Grey; Sujan Shresta; Bjoern Peters; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-11       Impact factor: 11.205

3.  CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.

Authors:  Raphaël M Zellweger; William W Tang; William E Eddy; Kevin King; Marisa C Sanchez; Sujan Shresta
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

4.  The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

Authors:  Beth D Kirkpatrick; Stephen S Whitehead; Kristen K Pierce; Cecilia M Tibery; Palmtama L Grier; Noreen A Hynes; Catherine J Larsson; Beulah P Sabundayo; Kawsar R Talaat; Anna Janiak; Marya P Carmolli; Catherine J Luke; Sean A Diehl; Anna P Durbin
Journal:  Sci Transl Med       Date:  2016-03-16       Impact factor: 17.956

5.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

6.  Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.

Authors:  Daniela Weiskopf; Michael A Angelo; John Sidney; Bjoern Peters; Sujan Shresta; Alessandro Sette
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

7.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

8.  Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Authors:  Janet C Lindow; Anna P Durbin; Stephen S Whitehead; Kristen K Pierce; Marya P Carmolli; Beth D Kirkpatrick
Journal:  Vaccine       Date:  2013-06-02       Impact factor: 3.641

Review 9.  Immune correlates for dengue vaccine development.

Authors:  Anon Srikiatkhachorn; In-Kyu Yoon
Journal:  Expert Rev Vaccines       Date:  2015-11-24       Impact factor: 5.217

Review 10.  Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

Authors:  Stephen S Whitehead
Journal:  Expert Rev Vaccines       Date:  2015-12-02       Impact factor: 5.217

View more
  36 in total

1.  Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

Authors:  Alba Grifoni; Michael Angelo; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Jason Botten; Jonathan Boyson; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 2.  Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

Review 3.  Transcriptomic immune profiles of human flavivirus-specific T-cell responses.

Authors:  Alba Grifoni; Yuan Tian; Alessandro Sette; Daniela Weiskopf
Journal:  Immunology       Date:  2020-01-07       Impact factor: 7.397

4.  Dengue vaccines: the road to failure or to success?

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

5.  Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells.

Authors:  Jennifer M Dan; Colin Havenar-Daughton; Kayla Kendric; Rita Al-Kolla; Kirti Kaushik; Sandy L Rosales; Ericka L Anderson; Christopher N LaRock; Pandurangan Vijayanand; Grégory Seumois; David Layfield; Ramsey I Cutress; Christian H Ottensmeier; Cecilia S Lindestam Arlehamn; Alessandro Sette; Victor Nizet; Marcella Bothwell; Matthew Brigger; Shane Crotty
Journal:  Sci Transl Med       Date:  2019-02-06       Impact factor: 17.956

6.  Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.

Authors:  Stephen J Popper; Fiona R Strouts; Janet C Lindow; Henry K Cheng; Magelda Montoya; Angel Balmaseda; Anna P Durbin; Stephen S Whitehead; Eva Harris; Beth D Kirkpatrick; David A Relman
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

Review 7.  The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis.

Authors:  Dustin R Glasner; Henry Puerta-Guardo; P Robert Beatty; Eva Harris
Journal:  Annu Rev Virol       Date:  2018-07-25       Impact factor: 10.431

Review 8.  T lymphocyte responses to flaviviruses - diverse cell populations affect tendency toward protection and disease.

Authors:  Luis Alberto Sanchez Vargas; Anuja Mathew; Alan L Rothman
Journal:  Curr Opin Virol       Date:  2020-08-15       Impact factor: 7.090

9.  Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model.

Authors:  John P Hanley; Huy A Tu; Julie A Dragon; Dorothy M Dickson; Roxana Del Rio-Guerra; Scott W Tighe; Korin M Eckstrom; Nicholas Selig; Samuel V Scarpino; Stephen S Whitehead; Anna P Durbin; Kristen K Pierce; Beth D Kirkpatrick; Donna M Rizzo; Seth Frietze; Sean A Diehl
Journal:  Nat Commun       Date:  2021-05-24       Impact factor: 17.694

10.  Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

Authors:  Alba Grifoni; John Pham; John Sidney; Patrick H O'Rourke; Sinu Paul; Bjoern Peters; Sheridan R Martini; Aruna D de Silva; Michael J Ricciardi; Diogo M Magnani; Cassia G T Silveira; Alvino Maestri; Priscilla R Costa; Luzia Maria de-Oliveira-Pinto; Elzinandes Leal de Azeredo; Paulo Vieira Damasco; Elizabeth Phillips; Simon Mallal; Aravinda M de Silva; Matthew Collins; Anna Durbin; Sean A Diehl; Cristhiam Cerpas; Angel Balmaseda; Guillermina Kuan; Josefina Coloma; Eva Harris; James E Crowe; Mars Stone; Phillip J Norris; Michael Busch; Hector Vivanco-Cid; Josephine Cox; Barney S Graham; Julie E Ledgerwood; Lance Turtle; Tom Solomon; Esper G Kallas; David I Watkins; Daniela Weiskopf; Alessandro Sette
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.